Acalabrutinib + Rabeprazole

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infectious Disease

Conditions

Infectious Disease

Trial Timeline

Jul 20, 2020 → Aug 28, 2020

NCT ID

NCT04489797

About Acalabrutinib + Rabeprazole

Acalabrutinib + Rabeprazole is a phase 1 stage product being developed by AstraZeneca for Infectious Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04489797. Target conditions include Infectious Disease.

What happened to similar drugs?

4 of 19 similar drugs in Infectious Disease were approved

Approved (4) Terminated (4) Active (11)

✅AdalimumabAbbVieApproved

✅Daptomycin + Standard of Care (SOC)MerckApproved

✅TigecyclinePfizerApproved

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

🔄LevofloxacinJohnson & JohnsonPhase 3

🔄Tedizolid Phophate + Antibiotic comparator + Aztreonam + MetronidazoleMerckPhase 3

❌Daptomycin + Vancomycin + TeicoplaninNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04489797	Phase 1	Completed	Jul 20, 2020	Aug 28, 2020	Infectious Disease

Competing Products

20 competing products in Infectious Disease

See all competitors

Product	Company	Stage	Hype Score
levofloxacin	Johnson & Johnson	Phase 2/3	38
Levofloxacin	Johnson & Johnson	Phase 3	40
Adalimumab	AbbVie	Approved	43
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam	Merck	Phase 2	35
Daptomycin + Standard of Care (SOC)	Merck	Approved	43
MK-7655 + Imipenem + Cilastatin + Caffeine + Midazolam + Omeprazole	Merck	Phase 1	29
TR-701 200 mg + TR-701 300 mg + TR-701 400 mg	Merck	Phase 2	35
Tedizolid Phophate + Antibiotic comparator + Aztreonam + Metronidazole	Merck	Phase 3	40
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
Daptomycin + Vancomycin + Teicoplanin	Novartis	Phase 3	32
PTK 0796 + linezolid + moxifloxacin	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
valacyclovir	Roche	Phase 1/2	32
Filgotinib + Placebo to match filgotinib + Prednisone	Gilead Sciences	Phase 2	27
Tigecycline + vancomycin with aztreonam	Pfizer	Phase 3	40
Tigecycline	Pfizer	Approved	43
Avibactam sodium/Ceftazidime hydrate	Pfizer	Pre-clinical	33